Post-Graduation Program in Clinical and Experimental Pathophysiology, State University of Rio de Janeiro (UERJ), Rio de Janeiro, Brazil.
Department of Applied Nutrition, Nutrition Institute, State University of Rio de Janeiro (UERJ), Rio de Janeiro, Brazil; Human Nutrition Research Unit, Department of Agricultural, Food and Nutritional Science, Division of Human Nutrition, University of Alberta, Alberta, Canada.
Clin Nutr. 2023 Jun;42(6):835-847. doi: 10.1016/j.clnu.2023.03.017. Epub 2023 Apr 5.
Obesity is a complex chronic metabolic disease that impairs health and reduces lifespan. Therefore, effective strategies for the prevention and treatment of obesity are necessary. Although several studies have demonstrated that gut dysbiosis is associated with obesity it, remains controversial whether the altered gut microbiota is a risk factor for or a consequence of obesity. Recent randomized clinical trials (RCTs) evaluating if gut microbiota modulation with probiotics favors weight loss present conflicting results, which can be attributed to the heterogeneity in the study designs. The aim of this paper is to make a comprehensive review describing the heterogeneity of interventions and body adiposity assessment methods of RCTs that evaluated the effects of probiotics on body weight and body adiposity in individuals with overweight and obesity. Thirty-three RCTs were identified through a search strategy. As main results we observed that ∼30% of the RCTs reported a significant decrease in body weight and body mass index (BMI) and ∼50% found a significant reduction in waist circumference and total fat mass. The beneficial effects of probiotics were more consistent in trials with ≥12 weeks, probiotics dose ≥10 CFU/day, in capsules, sachets or powder, and without concomitant energy restriction. The evidence of probiotics effects on body adiposity may improve and be more consistent in future RCTs which include methodological characteristics such as longer duration, higher dose, non-dairy vehicle, non-concurrent energy restriction and use of more accurate measures of body fat deposits (e.g., body fat mass and waist circumference) instead of body weight and BMI.
肥胖是一种复杂的慢性代谢性疾病,会损害健康并缩短寿命。因此,有必要采取有效的预防和治疗肥胖的策略。尽管有几项研究表明肠道菌群失调与肥胖有关,但肠道微生物群的改变是肥胖的危险因素还是后果仍存在争议。最近的一些随机临床试验(RCTs)评估了益生菌对肠道微生物群的调节是否有利于减肥,但结果存在冲突,这可能归因于研究设计的异质性。本文的目的是对评估益生菌对超重和肥胖个体体重和体脂肪影响的 RCTs 的干预措施和身体肥胖评估方法的异质性进行全面综述。通过搜索策略,确定了 33 项 RCT。主要结果表明,约 30%的 RCT 报道体重和体重指数(BMI)显著下降,约 50%的 RCT 发现腰围和总脂肪量显著减少。在持续时间≥12 周、益生菌剂量≥10 CFU/天、采用胶囊、小袋或粉末、不伴有能量限制的 RCT 中,益生菌的有益作用更为一致。未来的 RCT 纳入了更长的持续时间、更高的剂量、非乳制品载体、非同期能量限制以及使用更准确的体脂沉积测量方法(例如体脂肪量和腰围)来代替体重和 BMI,可能会改善并更一致地证明益生菌对体脂肪的作用。